Leveraging extracellular vesicle biology for novel tests and therapeutics for kidney fibrosis

Abstract

Key points:

Keywords

biomarkers / extracellular vesicles / kidney fibrosis / therapeutics

References

[1] Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024; 105(4S): S117-S314.

[2] Bordoni L, Kristensen AM, Sardella D, et al. Longitudinal tracking of acute kidney injury reveals injury propagation along the nephron. Nat Commun. 2023; 14(1): 4407.

[3] Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol. 2022; 18(9): 545-557.

[4] Zhu Y, Zha F, Tang B, et al. Exosomal hsa_circ_0125310 promotes cell proliferation and fibrosis in diabetic nephropathy via sponging miR-422a and targeting the IGF1R/p38 axis. J Cell Mol Med. 2022; 26(1): 151-162.

[5] Lu CC, Wang GH, Lu J, et al. Role of podocyte injury in glomerulosclerosis. Adv Exp Med Biol. 2019; 1165: 195-232.

[6] Borges FT, Melo SA, Ozdemir BC, et al. TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol. 2013; 24(3): 385-392.

[7] Gui Y, Liu S, Fu H, Zhou D. Editorial: tissue microenvironment in kidney diseases. Front Med (Lausanne). 2023; 10:1134043.

[8] Yáñez-Mó M, Siljander PRM, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4(1):27066.

[9] Ng MSY, Burger D, Svenningsen P, Martens E, Erdbrügger U, Braun F. Unlocking the potential of extracellular vesicles in nephrology: what does MISEV2023 add?. Kidney Int. 2025; 107(1): 44-50.

[10] Liu X, Miao J, Wang C, et al. Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis. Kidney Int. 2020; 97(6): 1181-1195.

[11] Loboda A, Sobczak M, Jozkowicz A, Dulak J. TGF-beta1/Smads and miR-21 in renal fibrosis and inflammation. Mediat Inflamm. 2016; 2016:8319283.

[12] Wu X, Gao Y, Xu L, et al. Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial-mesenchymal transition and dysfunction of podocytes. Sci Rep. 2017; 7(1): 9371.

[13] Wang YY, Tang LQ, Wei W. Berberine attenuates podocytes injury caused by exosomes derived from high glucose-induced mesangial cells through TGFbeta1-PI3K/AKT pathway. Eur J Pharmacol. 2018; 824: 185-192.

[14] Jin J, Shi Y, Gong J, et al. Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte. Stem Cell Res Ther. 2019; 10(1): 95.

[15] Liu JL, Zhang L, Huang Y, et al. Epsin1-mediated exosomal sorting of DLL4 modulates the tubular-macrophage crosstalk in diabetic nephropathy. Mol Ther. 2023; 31(5): 1451-1467.

[16] Sole C, Moline T, Vidal M, Ordi-Ros J, Cortes-Hernandez J. An exosomal urinary miRNA signature for early diagnosis of renal fibrosis in lupus nephritis. Cells. 2019; 8(8): 773.

[17] Yu M, Shen X, He W, Zheng D, He Q, Jin J. Mesangial cell-derived exosomal miR-4455 induces podocyte injury in IgA nephropathy by targeting ULK2. Oxid Med Cell Longev. 2022; 2022:1740770.

[18] Sendon PM, Pausch A, Gathmann A, et al. Extracellular vesicles of podocytes impact intraglomerular signaling and parietal epithelial cell activation: SA-OR55. J Am Soc Nephrol. 2024; 35(10S): 1009-1009.

[19] Li ZH, Guo XY, Quan XY, et al. The role of parietal epithelial cells in the pathogenesis of podocytopathy. Front Physiol. 2022; 13:832772.

[20] da Silva Novaes A, Borges FT, Maquigussa E, Varela VA, Dias MVS, Boim MA. Influence of high glucose on mesangial cell-derived exosome composition, secretion and cell communication. Sci Rep. 2019; 9(1): 6270.

[21] Jia Y, Xiong S, Chen H, Liu D, Wu X. Exosomes secreted by podocytes regulate the differentiation of Th17/Treg cells in idiopathic nephrotic syndrome. Heliyon. 2024; 10(18):e37866.

[22] Liu LL, Qin Y, Cai JF, et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin Immunol. 2011; 139(3): 314-320.

[23] Zhu QJ, Zhu M, Xu XX, Meng XM, Wu YG. Exosomes from high glucose-treated macrophages activate glomerular mesangial cells via TGF-beta1/Smad3 pathway in vivo and in vitro. FASEB J. 2019; 33(8): 9279-9290.

[24] Zhuang Y, Zheng H, Yang Y, Ni H. GABA alleviates high glucose-induced podocyte injury through dynamically altering the expression of macrophage M1/M2-derived exosomal miR-21a-5p/miR-25-3p. Biochem Biophys Res Commun. 2022; 618: 38-45.

[25] Wang Z, Sun W, Li R, Liu Y. miRNA-93-5p in exosomes derived from M2 macrophages improves lipopolysaccharide-induced podocyte apoptosis by targeting toll-like receptor 4. Bioengineered. 2022; 13(3): 7683-7696.

[26] Huang H, Liu H, Tang J, et al. M2 macrophage-derived exosomal miR-25-3p improves high glucose-induced podocytes injury through activation autophagy via inhibiting DUSP1 expression. IUBMB Life. 2020; 72(12): 2651-2662.

[27] Li Q, Liu J, Su R, Zhen J, Liu X, Liu G. Small extracellular vesicles-shuttled miR-23a-3p from mesenchymal stem cells alleviate renal fibrosis and inflammation by inhibiting KLF3/STAT3 axis in diabetic kidney disease. Int Immunopharmacol. 2024; 139:112667.

[28] Wang X, Kim CS, Adams BC, et al. Human proximal tubular epithelial cell-derived small extracellular vesicles mediate synchronized tubular ferroptosis in hypoxic kidney injury. Redox Biol. 2024; 70:103042.

[29] Li X, Peng X, Zhou X, et al. Small extracellular vesicles delivering lncRNA WAC-AS1 aggravate renal allograft ischemia‒reperfusion injury by inducing ferroptosis propagation. Cell Death Differ. 2023; 30(9): 2167-2186.

[30] Chen J, Tang T-T, Cao J-Y, et al. KIM-1 augments hypoxia-induced tubulointerstitial inflammation through uptake of small extracellular vesicles by tubular epithelial cells. Mol Ther. 2023; 31(5): 1437-1450.

[31] Lu Y, Zhang R, Gu X, Wang X, Xi P, Chen X. Exosomes from tubular epithelial cells undergoing epithelial-to-mesenchymal transition promote renal fibrosis by M1 macrophage activation. FASEB Bioadv. 2023; 5(3): 101-113.

[32] Lv LL, Feng Y, Wu M, et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. Cell Death Differ. 2020; 27(1): 210-226.

[33] Jia Y, Zheng Z, Xue M, et al. Extracellular vesicles from albumin-induced tubular epithelial cells promote the M1 macrophage phenotype by targeting Klotho. Mol Ther. 2019; 27(8): 1452-1466.

[34] Lv LL, Feng Y, Wen Y, et al. Exosomal CCL2 from tubular epithelial cells is critical for albumin-induced tubulointerstitial inflammation. J Am Soc Nephrol. 2018; 29(3): 919-935.

[35] Li ZL, Lv LL, Tang TT, et al. HIF-1alpha inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation. Kidney Int. 2019; 95(2): 388-404.

[36] Carson WF 4th, Salter-Green SE, Scola MM, Joshi A, Gallagher KA, Kunkel SL. Enhancement of macrophage inflammatory responses by CCL2 is correlated with increased miR-9 expression and downregulation of the ERK1/2 phosphatase Dusp6. Cell Immunol. 2017; 314: 63-72.

[37] Jiang WJ, Xu CT, Du CL, et al. Tubular epithelial cell-to-macrophage communication forms a negative feedback loop via extracellular vesicle transfer to promote renal inflammation and apoptosis in diabetic nephropathy. Theranostics. 2022; 12(1): 324-339.

[38] Olofsson Bagge R, Berndtsson J, Urzì O, Lötvall J, Micaroni M, Crescitelli R. Three-dimensional reconstruction of interstitial extracellular vesicles in human liver as determined by electron tomography. J Extracell Vesicles. 2023; 12(12):12380.

[39] Wu L, Baan CC, Reijerkerk D, Hesselink DA, Boer K. Urinary extracellular vesicles in healthy individuals: positive correlation between podocyte and tubular vesicles independent of kidney function. J Nephrol. 2024; 37(9): 2675-2678.

[40] Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006; 69(2): 213-217.

[41] Sun IO, Santelli A, Abumoawad A, et al. Loss of renal peritubular capillaries in hypertensive patients is detectable by urinary endothelial microparticle levels. Hypertension. 2018; 72(5): 1180-1188.

[42] Mensà E, Guescini M, Giuliani A, et al. Small extracellular vesicles deliver miR-21 and miR-217 as pro-senescence effectors to endothelial cells. J Extracell Vesicles. 2020; 9(1):1725285.

[43] Shao Y, Lv C, Wu C, Zhou Y, Wang Q. Mir-217 promotes inflammation and fibrosis in high glucose cultured rat glomerular mesangial cells via Sirt1/HIF-1α signaling pathway. Diabetes Metab Res Rev. 2016; 32(6): 534-543.

[44] Wang Z, Shi D, Zhang N, Yuan T, Tao H. MiR-217 promotes endothelial cell senescence through the SIRT1/p53 signaling pathway. J Mol Histol. 2021; 52(2): 257-267.

[45] Zhong X, Tang T-T, Shen A-R, et al. Tubular epithelial cells-derived small extracellular vesicle-VEGF-A promotes peritubular capillary repair in ischemic kidney injury. NPJ Regener Med. 2022; 7(1): 73.

[46] Migneault F, Kim H, Doreille A, et al. Endothelial extracellular vesicle miR-423-5p regulates microvascular homeostasis and renal function after ischemia-reperfusion injury. JCI Insight. 2025; 10(10):e181937.

[47] Tsai YC, Hung WW, Chang WA, et al. Autocrine exosomal fibulin-1 as a target of MiR-1269b induces epithelial-mesenchymal transition in proximal tubule in diabetic nephropathy. Front Cell Dev Biol. 2021; 9:789716.

[48] Franzin R, Stasi A, Sallustio F, et al. Extracellular vesicles derived from patients with antibody-mediated rejection induce tubular senescence and endothelial to mesenchymal transition in renal cells. Am J Transplant. 2022; 22(9): 2139-2157.

[49] Barnes JL, Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 2011; 79(9): 944-956.

[50] Wu XM, Gao YB, Cui FQ, Zhang N. Exosomes from high glucose-treated glomerular endothelial cells activate mesangial cells to promote renal fibrosis. Biol Open. 2016; 5(4): 484-491.

[51] Ling L, Tan Z, Zhang C, et al. CircRNAs in exosomes from high glucose-treated glomerular endothelial cells activate mesangial cells. Am J Transl Res. 2019; 11(8): 4667-4682.

[52] Liu Z, Liu X, Zhou Y, et al. Extracellular vesicles play a central role in linking podocyte injury to mesangial activation in glomerular disease. Theranostics. 2025; 15(11): 5121-5137.

[53] Gewin LS. Renal fibrosis: primacy of the proximal tubule. Matrix Biol. 2018; 68–69: 248-262.

[54] Wen J, Ma Z, Livingston MJ, et al. Decreased secretion and profibrotic activity of tubular exosomes in diabetic kidney disease. Am J Physiol Renal Physiol. 2020; 319(4): F664-F673.

[55] Hu R, Li X, Peng C, et al. miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes. Br Med J (Clin Res Ed). 2020; 8(1):e001101.

[56] Chen S, Zhang M, Li J, et al. β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis. J Extracell Vesicles. 2022; 11(3):e12203.

[57] Zhou X, Zhao S, Li W, et al. Tubular cell-derived exosomal miR-150-5p contributes to renal fibrosis following unilateral ischemia-reperfusion injury by activating fibroblast in vitro and in vivo. Int J Biol Sci. 2021; 17(14): 4021-4033.

[58] Guan H, Peng R, Mao L, Fang F, Xu B, Chen M. Injured tubular epithelial cells activate fibroblasts to promote kidney fibrosis through miR-150-containing exosomes. Exp Cell Res. 2020; 392(2):112007.

[59] Zhao S, Li W, Yu W, et al. Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys. Theranostics. 2021; 11(18): 8660-8673.

[60] Zhou D, Tan RJ, Liu Y. Sonic hedgehog signaling in kidney fibrosis: a master communicator. Sci China Life Sci. 2016; 59(9): 920-929.

[61] Dai R, Cheng M, Peng C-Y, et al. Renal tubular epithelial cell-derived exosomal miR-330-3p plays a key role in fibroblast activation and renal fibrosis by regulating CREBBP. Stem Cell Res Ther. 2025; 16(1): 203.

[62] Huang Y, Li R, Zhang L, et al. Extracellular vesicles from high glucose-treated podocytes induce apoptosis of proximal tubular epithelial cells. Front Physiol. 2020; 11:579296.

[63] Jeon JS, Kim E, Bae YU, et al. microRNA in extracellular vesicles released by damaged podocytes promote apoptosis of renal tubular epithelial cells. Cells. 2020; 9(6): 1409.

[64] Su H, Qiao J, Hu J, et al. Podocyte-derived extracellular vesicles mediate renal proximal tubule cells dedifferentiation via microRNA-221 in diabetic nephropathy. Mol Cell Endocrinol. 2020; 518:111034.

[65] Ren FJ, Yao Y, Cai XY, Cai YT, Su Q, Fang GY. MiR-149-5p: an important miRNA regulated by competing endogenous RNAs in diverse human cancers. Front Oncol. 2021; 11:743077.

[66] Munkonda MN, Akbari S, Landry C, et al. Podocyte-derived microparticles promote proximal tubule fibrotic signaling via p38 MAPK and CD36. J Extracell Vesicles. 2018; 7(1):1432206.

[67] Tsai YC, Kuo MC, Hung WW, et al. Proximal tubule-derived exosomes contribute to mesangial cell injury in diabetic nephropathy via miR-92a-1-5p transfer. Cell Commun Signal. 2023; 21(1): 10.

[68] Song A, Wang M, Xie K, et al. Exosomal let-7b-5p deriving from parietal epithelial cells attenuate renal fibrosis through suppression of TGFβR1 and ARID3a in obstructive kidney disease. FASEB J. 2024; 38(19):e70085.

[69] Dhaun N, Bellamy CO, Cattran DC, Kluth DC. Utility of renal biopsy in the clinical management of renal disease. Kidney Int. 2014; 85(5): 1039-1048.

[70] Ramachandran R, Sulaiman S, Chauhan P, et al. Challenges in diagnosis and management of glomerular disease in resource-limited settings. Kidney Int Rep. 2022; 7(10): 2141-2149.

[71] Ugarte F, Santapau D, Gallardo V, et al. Urinary extracellular vesicles as a source of NGAL for diabetic kidney disease evaluation in children and adolescents with type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2021; 12:654269.

[72] Erozenci LA, Pham TV, Piersma SR, et al. Simple urine storage protocol for extracellular vesicle proteomics compatible with at-home self-sampling. Sci Rep. 2021; 11(1):20760.

[73] Blijdorp CJ, Hartjes TA, Wei KY, et al. Nephron mass determines the excretion rate of urinary extracellular vesicles. J Extracell Vesicles. 2022; 11(1):e12181.

[74] Lv CY, Ding WJ, Wang YL, et al. A PEG-based method for the isolation of urinary exosomes and its application in renal fibrosis diagnostics using cargo miR-29c and miR-21 analysis. Int Urol Nephrol. 2018; 50(5): 973-982.

[75] Saejong S, Townamchai N, Somparn P, et al. MicroRNA-21 in plasma exosome, but not from whole plasma, as a biomarker for the severe interstitial fibrosis and tubular atrophy (IF/TA) in post-renal transplantation. Asian Pac J Allergy Immunol. 2022; 40(1): 94-102.

[76] Kim MY, Shin H, Moon HW, Park YH, Park J, Lee JY. Urinary exosomal microRNA profiling in intermediate-risk prostate cancer. Sci Rep. 2021; 11(1): 7355.

[77] Yang FK, Tian C, Zhou LX, et al. The value of urinary exosomal microRNA-21 in the early diagnosis and prognosis of bladder cancer. Kaohsiung J Med Sci. 2024; 40(7): 660-670.

[78] Kao HW, Pan CY, Lai CH, et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget. 2017; 8(34): 56389-56397.

[79] Jenike AE, Halushka MK. miR-21: a non-specific biomarker of all maladies. Biomark Res. 2021; 9(1): 18.

[80] Nguyen TTP, Suman KH, Nguyen TB, Nguyen HT, Do DN. The role of miR-29s in human cancers – an update. Biomedicines. 2022; 10(9): 2121.

[81] Du L, Jiang X, Duan W, et al. Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2017; 8(25): 40832-40842.

[82] Chang Z, Chen B, Wang S, et al. Organ-specific cancer biomarker identification: a ten-year single-center study in southern China. BMC Cancer. 2025; 25(1): 820.

[83] Tonelli M, Wiebe N, Manns BJ, et al. Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open. 2018; 1(7): e184852-e184852.

[84] Chun-Yan L, Zi-Yi Z, Tian-Lin Y, et al. Liquid biopsy biomarkers of renal interstitial fibrosis based on urinary exosome. Exp Mol Pathol. 2018; 105(2): 223-228.

[85] Lv LL, Cao YH, Ni HF, et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol. 2013; 305(8): F1220-F1227.

[86] Yu Y, Bai F, Qin N, et al. Non-proximal renal tubule-derived urinary exosomal miR-200b as a biomarker of renal fibrosis. Nephron. 2018; 139(3): 269-282.

[87] Kim MJ, Kwon HE, Jang H-W, et al. Multicenter, prospective, observational study for urinary exosomal biomarkers of kidney allograft fibrosis. Sci Rep. 2024; 14(1):20319.

[88] Aomatsu A, Kaneko S, Yanai K, et al. MicroRNA expression profiling in acute kidney injury. Transl Res. 2022; 244: 1-31.

[89] Ibrahim AA, Soliman HM, El-Lebedy D, et al. Expression of exosomal miR-21 and miR-29 in serum of children and adolescents with T1DM and persistent microalbuminuria. Gene Rep. 2019; 16:100461.

[90] Huang H, Huang X, Luo S, et al. The microRNA MiR-29c alleviates renal fibrosis via TPM1-mediated suppression of the Wnt/beta-catenin pathway. Front Physiol. 2020; 11: 331.

[91] Xiao J, Meng XM, Huang XR, et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther. 2012; 20(6): 1251-1260.

[92] Matsumoto Y, Itami S, Kuroda M, Yoshizato K, Kawada N, Murakami Y. MiR-29a assists in preventing the activation of human stellate cells and promotes recovery from liver fibrosis in mice. Mol Ther. 2016; 24(10): 1848-1859.

[93] Sassi Y, Avramopoulos P, Ramanujam D, et al. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun. 2017; 8(1): 1614.

[94] Dwivedi OP, Barreiro K, Käräjämäki A, et al. Genome-wide mRNA profiling in urinary extracellular vesicles reveals stress gene signature for diabetic kidney disease. iScience. 2023; 26(5):106686.

[95] Burrello J, Monticone S, Burrello A, et al. Identification of a serum and urine extracellular vesicle signature predicting renal outcome after kidney transplant. Nephrol Dial Transplant. 2023; 38(3): 764-777.

[96] Xue R, Yiu WH, Chan KW, et al. Long non-coding RNA NEAT1, NOD-like receptor family protein 3 inflammasome, and acute kidney injury. J Am Soc Nephrol. 2024; 35(8): 998-1015.

[97] Li G, Sun L, Xin C, et al. A hypoxia-responsive tRNA-derived small RNA confers renal protection through RNA autophagy. Science. 2025; 389(6763):eadp5384.

[98] de Goede OM, Nachun DC, Ferraro NM, et al. Population-scale tissue transcriptomics maps long non-coding RNAs to complex disease. Cell. 2021; 184(10): 2633-2648.e2619.

[99] Tutrone R, Lowentritt B, Neuman B, et al. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer—an interim analysis. Prostate Cancer Prostatic Dis. 2023; 26(3): 596-601.

[100] Winn-Deen ES, Bortolin LT, Gusenleitner D, et al. Improving specificity for ovarian cancer screening using a novel extracellular vesicle-based blood test: performance in a training and verification cohort. J Mol Diagn. 2024; 26(12): 1129-1148.

[101] Droste M, Puhka M, van Royen ME, et al. Roadblocks of urinary EV biomarkers: moving toward the clinic. J Extracell Vesicles. 2025; 14(7):e70120.

[102] Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024; 13(2):e12404.

[103] Van Deun J, Mestdagh P, Agostinis P, et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods. 2017; 14(3): 228-232.

[104] Ji C, Zhang J, Zhu Y, et al. Exosomes derived from hucMSC attenuate renal fibrosis through CK1delta/beta-TRCP-mediated YAP degradation. Cell Death Dis. 2020; 11(5): 327.

[105] Taiyab A, Belahlou Y, Wong V, et al. Understanding the role of Yes-associated protein (YAP) signaling in the transformation of lens epithelial cells (EMT) and fibrosis. Biomolecules. 2023; 13(12): 1767.

[106] Guo Q, Li P, Chen M, et al. Exosomes from human umbilical cord stem cells suppress macrophage-to-myofibroblast transition, alleviating renal fibrosis. Inflammation. 2024; 47(6): 2094-2107.

[107] Rey-Serra C, Tituana J, Lin T, et al. Reciprocal regulation between the molecular clock and kidney injury. Life Sci Alliance. 2023; 6(10):e202201886.

[108] Wang X, Huang S, Li X, Cheng H. The transfer of USP25 by exosomes of adipose tissue-derived mesenchymal stem cells ameliorates diabetic nephropathy through stabilizing SMAD7 expression. Chem Biol Drug Des. 2025; 105(5):e70118.

[109] Choi HY, Lee HG, Kim BS, et al. Mesenchymal stem cell-derived microparticles ameliorate peritubular capillary rarefaction via inhibition of endothelial-mesenchymal transition and decrease tubulointerstitial fibrosis in unilateral ureteral obstruction. Stem Cell Res Ther. 2015; 6(1): 18.

[110] Liu Y, Guo W, Guo Y, Chen X, Liu W. Bone marrow mesenchymal stem cell-derived exosomes improve renal fibrosis via regulating Smurf 2/Smad 7. Front Biosci (Landmark Ed). 2022; 27(1): 17.

[111] Alasmari WA, Abdelfattah-Hassan A, El-Ghazali HM, et al. Exosomes derived from BM-MSCs mitigate the development of chronic kidney damage post-menopause via interfering with fibrosis and apoptosis. Biomolecules. 2022; 12(5): 663.

[112] Kholia S, Herrera Sanchez MB, Cedrino M, et al. Mesenchymal stem cell derived extracellular vesicles ameliorate kidney injury in aristolochic acid nephropathy. Front Cell Dev Biol. 2020; 8: 188.

[113] Ebrahim N, Ahmed IA, Hussien NI, et al. Mesenchymal stem cell-derived exosomes ameliorated diabetic nephropathy by autophagy induction through the mTOR signaling pathway. Cells. 2018; 7(12): 226.

[114] Ji C, Zhang J, Shi L, et al. Engineered extracellular vesicle-encapsulated CHIP as novel nanotherapeutics for treatment of renal fibrosis. NPJ Regen Med. 2024; 9(1): 3.

[115] Chen L, Wang Y, Li S, et al. Exosomes derived from GDNF-modified human adipose mesenchymal stem cells ameliorate peritubular capillary loss in tubulointerstitial fibrosis by activating the SIRT1/eNOS signaling pathway. Theranostics. 2020; 10(20): 9425-9442.

[116] Jin J, Qian F, Zheng D, He W, Gong J, He Q. Mesenchymal stem cells attenuate renal fibrosis via exosomes-mediated delivery of microRNA Let-7i-5p antagomir. Int J Nanomed. 2021; 16: 3565-3578.

[117] Tan J, Feng L, Ragavan ND, Chai Theam O, Li X. The promotive effect of Caspase-11 overexpression in a rat model of chronic kidney disease and the therapeutic efficacy of exosome-delivered siRNA in inhibiting Caspase-11. Biochem Biophys Res Commun. 2024; 741:151013.

[118] Miao NJ, Xie HY, Xu D, et al. Caspase-11 promotes renal fibrosis by stimulating IL-1beta maturation via activating caspase-1. Acta Pharmacol Sin. 2019; 40(6): 790-800.

[119] Ajay AK, Zhao L, Vig S, et al. Deletion of STAT3 from Foxd1 cell population protects mice from kidney fibrosis by inhibiting pericytes trans-differentiation and migration. Cell Rep. 2022; 38(10):110473.

[120] Morimoto K, Nakashima A, Ishiuchi N, et al. Renal protective effects of extracellular vesicle-encapsulated tumor necrosis factor-α-induced protein 6 derived from mesenchymal stem cells. Stem Cells. 2025; 43(5):sxaf022.

[121] Chen H, Deng J, Gao H, et al. Involvement of the SIRT1-NLRP3 pathway in the inflammatory response. Cell Commun Signal. 2023; 21(1): 185.

[122] Zhang X, Zhao J, Ge R, et al. Arg-Gly-Asp engineered mesenchymal stem cells as targeted nanotherapeutics against kidney fibrosis by modulating m6A. Acta Biomater. 2025; 198: 85-101.

[123] Fujimoto D, Umemoto S, Mizumoto T, et al. Alvespimycin is identified as a novel therapeutic agent for diabetic kidney disease by chemical screening targeting extracellular vesicles. Sci Rep. 2025; 15(1):14436.

[124] Silva TF, Hutchins E, Zhao W, et al. Extracellular vesicle heterogeneity through the lens of multiomics. Cell Rep Med. 2025; 6(7):102161.

[125] Jalali M, del Real Mata C, Montermini L, et al. MoS2-plasmonic nanocavities for Raman spectra of single extracellular vesicles reveal molecular progression in glioblastoma. ACS Nano. 2023; 17(13): 12052-12071.

[126] Patel DB, Gray KM, Santharam Y, Lamichhane TN, Stroka KM, Jay SM. Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell-derived extracellular vesicles. Bioeng Transl Med. 2017; 2(2): 170-179.

[127] Mol EA, Goumans M-J, Doevendans PA, Sluijter JPG, Vader P. Higher functionality of extracellular vesicles isolated using size-exclusion chromatography compared to ultracentrifugation. Nanomed Nanotechnol Biol Med. 2017; 13(6): 2061-2065.

[128] Madel RJ, Börger V, Dittrich R, et al. Independent human mesenchymal stromal cell–derived extracellular vesicle preparations differentially attenuate symptoms in an advanced murine graft-versus-host disease model. Cytotherapy. 2023; 25(8): 821-836.

[129] Nishida-Aoki N, Izumi Y, Takeda H, Takahashi M, Ochiya T, Bamba T. Lipidomic analysis of cells and extracellular vesicles from high- and low-metastatic triple-negative breast cancer. Metabolites. 2020; 10(2): 67.

[130] Giebel B, Lim SK. Overcoming challenges in MSC-sEV therapeutics: insights and advances after a decade of research. Cytotherapy. 2025; 27(7): 843-848.

[131] Carney RP, Mizenko RR, Bozkurt BT, et al. Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications. Nat Nanotechnol. 2025; 20(1): 14-25.

[132] Kang M, Jordan V, Blenkiron C, Chamley LW. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J Extracell Vesicles. 2021; 10(8):e12085.

[133] Li Y, Hu C, Zhai P, et al. Fibroblastic reticular cell-derived exosomes are a promising therapeutic approach for septic acute kidney injury. Kidney Int. 2024; 105(3): 508-523.

[134] Huang Y, Jiang K, Zhang X, Chung EJ. The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles. Bioeng Transl Med. 2020; 5(3):e10173.

[135] Wang J, Masehi-Lano JJ, Chung EJ. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomater Sci. 2017; 5(8): 1450-1459.

[136] Chade AR, Bidwell GL. Novel drug delivery technologies and targets for renal disease. Hypertension. 2022; 79(9): 1937-1948.

[137] Driedonks T, Jiang L, Carlson B, et al. Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally to Macaca nemestrina. J Extracell Biol. 2022; 1(10):e59.

[138] Liang X, Niu Z, Galli V, et al. Extracellular vesicles engineered to bind albumin demonstrate extended circulation time and lymph node accumulation in mouse models. J Extracell Vesicles. 2022; 11(7):e12248.

[139] Zheng W, Schürz M, Wiklander RJ, et al. Surface display of functional moieties on extracellular vesicles using lipid anchors. J Controlled Release. 2023; 357: 630-640.

[140] Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017; 546(7659): 498-503.

[141] Simon L, Constanzo J, Terraza-Aguirre C, et al. Surface modification of extracellular vesicles with polyoxazolines to enhance their plasma stability and tumor accumulation. Biomaterials. 2025; 313:122748.

[142] Yang Q, Jacobs TM, McCallen JD, et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal Chem. 2016; 88(23): 11804-11812.

[143] Nassar W, El-Ansary M, Sabry D, et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res. 2016; 20(1): 21.

[144] Nazari H, Alborzi F, Heirani-Tabasi A, et al. Evaluating the safety and efficacy of mesenchymal stem cell-derived exosomes for treatment of refractory perianal fistula in IBD patients: clinical trial phase I. Gastroenterol Rep. 2022; 10:goac075.

[145] Lightner AL, Sengupta V, Qian S, et al. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: a randomized, placebo-controlled dosing clinical trial. Chest. 2023; 164(6): 1444-1453.

[146] Dehghani L, Rostamirad S, Asilian A, et al. Efficacy of placental-derived mesenchymal stem cell exosome therapy in treating androgenetic alopecia: a clinical trial study. Preprint-Research Square. 2024. Version 1.

[147] Osborn E, Ransom JT, Shulman A, et al. A novel extracellular vesicle paradigm for the treatment of COVID-19 induced acute respiratory distress syndrome (ARDS). Respir Med Case Rep. 2024; 51:102087.

[148] Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005; 3(1): 10.

[149] Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016; 5(4):e1071008.

[150] Grigoropoulos I, Tsioulos G, Kastrissianakis A, et al. The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS. Respir Res. 2024; 25(1): 151.

[151] Shapira S, Ben Shimon M, Hay-Levi M, et al. A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyond. EMBO Mol Med. 2022; 14(9):e15997.

[152] Hyun S, Choi H, Sub Y, et al. Safety and anti-inflammatory effects of engineered extracellular vesicles (ILB-202) for NF-κB inhibition: a double-blind, randomized, placebo-controlled phase 1 trial. J Extracell Vesicles. 2025; 14(9):e70141.

[153] McLeod C. Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation. National Institutes of Health; 2025.

[154] Pumford AD, Staricha KL, Kunkel ET, Armstrong MF, Behfar A, Van Abel KM. Exosome therapy for a nonhealing scalp wound following chemoradiation and surgical therapy. Mayo Clin Proc. 2024; 99(6): 1006-1012.

[155] Menasché P, Renault NK, Hagège A, et al. First-in-man use of a cardiovascular cell-derived secretome in heart failure. Case report. EBioMedicine. 2024; 103:105145.

[156] Sheng S, Zou M, Yang Y, et al. miR-23a-3p regulates the inflammatory response and fibrosis in diabetic kidney disease by targeting early growth response 1. In Vitro Cell Dev Biol Anim. 2021; 57(8): 763-774.

[157] Zhou H, Hasni SA, Perez P, et al. miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1. J Am Soc Nephrol. 2013; 24(7): 1073-1087.

[158] Zhang Y, Zhang GX, Che LS, Shi SH, Lin WY. miR-19 promotes development of renal fibrosis by targeting PTEN-mediated epithelial-mesenchymal transition. Int J Clin Exp Pathol. 2020; 13(4): 642-654.

[159] Eyileten C, Nowak A, Shahzadi A, et al. Diagnostic ability of miR-19a and Let-7f along with platelet and leukocyte extracellular vesicles in acute ischemic stroke patients. Eur Heart J. 2022; 43(suppl_2):ehac544.3055.

[160] Wang L, Wu J, Ye N, et al. Plasma-derived exosome MiR-19b acts as a diagnostic marker for pancreatic cancer. Front Oncol. 2021; 11:739111.

[161] Rizwan M, Mahjabeen I, Ashraf NS, Arshad M, Haris MS, Kayani MA. Dysregulation of exosomal miRNAs and their related genes in head and neck cancer patients. Future Oncol. 2024; 20(21): 1479-1493.

[162] Dejima H, Iinuma H, Kanaoka R, Matsutani N, Kawamura M. Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett. 2017; 13(3): 1256-1263.

[163] Soeda N, Iinuma H, Suzuki Y, et al. Plasma exosome-encapsulated microRNA-21 and microRNA-92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer. Oncol Lett. 2019; 18(5): 4467-4480.

[164] Hannafon BN, Trigoso YD, Calloway CL, et al. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 2016; 18(1): 90.

[165] Perez-Hernandez J, Martinez-Arroyo O, Ortega A, et al. Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis. J Nephrol. 2021; 34(4): 1157-1167.

[166] Perez-Hernandez J, Olivares D, Forner MJ, et al. Urinary exosome miR-146a is a potential marker of albuminuria in essential hypertension. J Transl Med. 2018; 16(1): 228.

[167] Perez-Hernandez J, Forner MJ, Pinto C, Chaves FJ, Cortes R, Redon J. Increased urinary exosomal microRNAs in patients with systemic lupus erythematosus. PLoS One. 2015; 10(9):e0138618.

[168] Butz H, Nofech-Mozes R, Ding Q, et al. Exosomal microRNAs are diagnostic biomarkers and can mediate cell–cell communication in renal cell carcinoma. Eur Urol Focus. 2016; 2(2): 210-218.

[169] Sapre N, Macintyre G, Clarkson M, et al. A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. Br J Cancer. 2016; 114(4): 454-462.

[170] Cao Y, Shi Y, Wang Y, et al. Exosomal hsa_circ_0008925 from urine is related to chronic renal fibrosis. Dis Markers. 2022; 2022(1):1899282.

[171] Shi Y, Chen Y, Xiao Z, Wang Y, Fu C, Cao Y. Renal tubular epithelial cell–derived hsa_circ_0008925 from urine is related to chronic renal fibrosis. J Cell Mol Med. 2025; 29(1):e70335.

[172] Sole C, Cortes-Hernandez J, Felip ML, Vidal M, Ordi-Ros J. miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. Nephrol Dial Transplant. 2015; 30(9): 1488-1496.

[173] Jeong KH, Kim JS, Hwang HS, et al. Urinary exosomal microRNAs are potential diagnostic and prognostic biomarkers in IgA nephropathy patients: PO1846. J Am Soc Nephrol. 2020; 31(10S): 575-575.

[174] Lin X, Luo C, He D, et al. Urinary miRNA-29a-3p levels are associated with metabolic parameters via regulation of IGF1 in patients with metabolic syndrome. Biomed Rep. 2019; 10(4): 250-258.

[175] Chen D, Zhang G, Li Y, et al. Up-regulation of urinary exosomal hsa-microRNA-200b-3p and hsa-microRNA-206 in patients of steroid-induced osteonecrosis of femoral head. Am J Transl Res. 2021; 13(7): 7574-7590.

[176] Savolainen K, Scaravilli M, Ilvesmäki A, et al. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes. 2020; 13(1): 311.

[177] Lv L-L, Cao Y-H, Pan M-M, et al. CD2AP mRNA in urinary exosome as biomarker of kidney disease. Clin Chim Acta. 2014; 428: 26-31.

[178] Cao Y, Shi Y, Yang Y, et al. Urinary exosomes derived circRNAs as biomarkers for chronic renal fibrosis. Ann Med. 2022; 54(1): 1966-1976.

[179] Lu Y, Yang L, Chen X, Liu J, Nie A, Chen X. Bone marrow mesenchymal stem cell-derived exosomes improve renal fibrosis by reducing the polarisation of M1 and M2 macrophages through the activation of EP2 receptors. IET Nanobiotechnol. 2022; 16(1): 14-24.

[180] Shi Z, Wang Q, Zhang Y, Jiang D. Extracellular vesicles produced by bone marrow mesenchymal stem cells attenuate renal fibrosis, in part by inhibiting the RhoA/ROCK pathway, in a UUO rat model. Stem Cell Res Ther. 2020; 11(1): 253.

[181] Wang Y, Lu D, Lv S, Liu X, Liu G. Mesenchymal stem cell-derived exosomes ameliorate diabetic kidney disease through NOD2 signaling pathway. Ren Fail. 2024; 46(2):2381597.

[182] Li Q, Liu J, Su R, Zhen J, Liu X, Liu G. Small extracellular vesicles-shuttled miR-23a-3p from mesenchymal stem cells alleviate renal fibrosis and inflammation by inhibiting KLF3/STAT3 axis in diabetic kidney disease. Int Immunopharmacol. 2024; 139:112667.

[183] Jin J, Wang Y, Zhao L, Zou W, Tan M, He Q. Exosomal miRNA-215-5p derived from adipose-derived stem cells attenuates epithelial–mesenchymal transition of podocytes by inhibiting ZEB2. Biomed Res Int. 2020; 2020(1):2685305.

[184] Duan YR, Chen BP, Chen F, et al. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte. J Cell Mol Med. 2021; 25(23): 10798-10813.

[185] Wang Y, Pang Z, He W, Ren P, He Q, Jin J. LncRNA HOXB3OS improves high glucose-mediated podocyte damage and progression of diabetic kidney disease through enhancing SIRT1 mRNA stability. Biomed Pharmacother. 2025; 182:117770.

[186] Tan J, Feng L, Ragavan ND, Chai Theam O, Li X. The promotive effect of Caspase-11 overexpression in a rat model of chronic kidney disease and the therapeutic efficacy of exosome-delivered siRNA in inhibiting Caspase-11. Biochem Biophys Res Commun. 2024; 741:151013.

[187] Raimondo S, Nikolic D, Conigliaro A, et al. Preliminary results of CitraVes™ effects on low density lipoprotein cholesterol and waist circumference in healthy subjects after 12 weeks: a pilot open-label study. Metabolites. 2021; 11(5): 276.

[188] Hendrix A, Lippens L, Pinheiro C, et al. Extracellular vesicle analysis. Nat Rev Methods Primers. 2023; 3(1): 56.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.